Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide: synthesis, binding affinity and intrinsic activity for MT(1) and MT(2) melatonin receptors. 2011

Gilberto Spadoni, and Annalida Bedini, and Pierfrancesco Orlando, and Simone Lucarini, and Giorgio Tarzia, and Marco Mor, and Silvia Rivara, and Valeria Lucini, and Marilou Pannacci, and Francesco Scaglione
Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo, Piazza Rinascimento 6, 61029 Urbino, Italy. gilberto.spadoni@uniurb.it

We report the synthesis, binding properties and intrinsic activity at MT(1) and MT(2) melatonin receptors of new dimeric melatonin receptor ligands in which two units of the monomeric agonist N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide (1) are linked together through different anchor points. Dimerization of compound 1 through the methoxy substituent leads to a substantial improvement in selectivity for the MT(1) receptor, and to a partial agonist behavior. Compound 3a, with a trimethylene linker, was the most selective for the MT(1) subtype (112-fold selectivity) and compound 3d, characterized by a hexamethylene spacer, had the highest MT(1) binding affinity (pK(iMT1)=8.47) and 54-fold MT(1)-selectivity. Dimerization through the aniline nitrogen of 1 abolished MT(1) selectivity, leading to compounds with either a full agonist or an antagonist behavior depending on the nature of the linker.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D016475 3T3 Cells Cell lines whose original growing procedure consisted being transferred (T) every 3 days and plated at 300,000 cells per plate (J Cell Biol 17:299-313, 1963). Lines have been developed using several different strains of mice. Tissues are usually fibroblasts derived from mouse embryos but other types and sources have been developed as well. The 3T3 lines are valuable in vitro host systems for oncogenic virus transformation studies, since 3T3 cells possess a high sensitivity to CONTACT INHIBITION. 3T3 Cell,Cell, 3T3,Cells, 3T3
D044094 Receptors, Melatonin A family of G-protein-coupled receptors that are specific for and mediate the effects of MELATONIN. Activation of melatonin receptors has been associated with decreased intracellular CYCLIC AMP and increased hydrolysis of PHOSPHOINOSITIDES. Melatonin Receptors,MT3 Receptor,Mel(1c) Receptor,Melatonin MT3 Receptor,Receptor, Mel1c,Receptor, Melatonin,Receptor, Melatonin, 1C,Receptor, Melatonin, MT3,MT3 Receptor, Melatonin,Mel1c Receptor,Melatonin Receptor,Receptor, MT3,Receptor, Melatonin MT3
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D057809 HEK293 Cells A cell line generated from human embryonic kidney cells that were transformed with human adenovirus type 5. 293T Cells,HEK 293 Cell Line,HEK 293 Cells,Human Embryonic Kidney Cell Line 293,Human Kidney Cell Line 293,293 Cell, HEK,293 Cells, HEK,293T Cell,Cell, 293T,Cell, HEK 293,Cell, HEK293,Cells, 293T,Cells, HEK 293,Cells, HEK293,HEK 293 Cell,HEK293 Cell

Related Publications

Gilberto Spadoni, and Annalida Bedini, and Pierfrancesco Orlando, and Simone Lucarini, and Giorgio Tarzia, and Marco Mor, and Silvia Rivara, and Valeria Lucini, and Marilou Pannacci, and Francesco Scaglione
August 2007, Bioorganic & medicinal chemistry,
Gilberto Spadoni, and Annalida Bedini, and Pierfrancesco Orlando, and Simone Lucarini, and Giorgio Tarzia, and Marco Mor, and Silvia Rivara, and Valeria Lucini, and Marilou Pannacci, and Francesco Scaglione
May 2009, Acta crystallographica. Section E, Structure reports online,
Gilberto Spadoni, and Annalida Bedini, and Pierfrancesco Orlando, and Simone Lucarini, and Giorgio Tarzia, and Marco Mor, and Silvia Rivara, and Valeria Lucini, and Marilou Pannacci, and Francesco Scaglione
April 2010, Bioorganic & medicinal chemistry letters,
Gilberto Spadoni, and Annalida Bedini, and Pierfrancesco Orlando, and Simone Lucarini, and Giorgio Tarzia, and Marco Mor, and Silvia Rivara, and Valeria Lucini, and Marilou Pannacci, and Francesco Scaglione
September 2010, Bioorganic & medicinal chemistry,
Gilberto Spadoni, and Annalida Bedini, and Pierfrancesco Orlando, and Simone Lucarini, and Giorgio Tarzia, and Marco Mor, and Silvia Rivara, and Valeria Lucini, and Marilou Pannacci, and Francesco Scaglione
March 2003, Acta crystallographica. Section C, Crystal structure communications,
Gilberto Spadoni, and Annalida Bedini, and Pierfrancesco Orlando, and Simone Lucarini, and Giorgio Tarzia, and Marco Mor, and Silvia Rivara, and Valeria Lucini, and Marilou Pannacci, and Francesco Scaglione
January 2000, Drug design and discovery,
Gilberto Spadoni, and Annalida Bedini, and Pierfrancesco Orlando, and Simone Lucarini, and Giorgio Tarzia, and Marco Mor, and Silvia Rivara, and Valeria Lucini, and Marilou Pannacci, and Francesco Scaglione
January 1996, Journal of receptor and signal transduction research,
Gilberto Spadoni, and Annalida Bedini, and Pierfrancesco Orlando, and Simone Lucarini, and Giorgio Tarzia, and Marco Mor, and Silvia Rivara, and Valeria Lucini, and Marilou Pannacci, and Francesco Scaglione
March 2000, British journal of pharmacology,
Gilberto Spadoni, and Annalida Bedini, and Pierfrancesco Orlando, and Simone Lucarini, and Giorgio Tarzia, and Marco Mor, and Silvia Rivara, and Valeria Lucini, and Marilou Pannacci, and Francesco Scaglione
May 1996, The Journal of pharmacology and experimental therapeutics,
Gilberto Spadoni, and Annalida Bedini, and Pierfrancesco Orlando, and Simone Lucarini, and Giorgio Tarzia, and Marco Mor, and Silvia Rivara, and Valeria Lucini, and Marilou Pannacci, and Francesco Scaglione
May 1994, Journal of medicinal chemistry,
Copied contents to your clipboard!